Exact Sciences stock (US30063P1057): Q1 2026 revenue growth driven by Cologuard and Oncotype DX

Exact Sciences Corp., a leader in precision oncology diagnostics, released its first quarter 2026 financial results on May 8, 2026. The company posted revenue of $1.62 billion, up 12% year-over-year, driven by strong performance in its core screening and cancer diagnostics segments, according to Exact Sciences investor relations as of 05/08/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Exact Sciences Corp.: core business model

Exact Sciences develops and markets molecular tests for cancer screening and diagnosis. Its flagship product, Cologuard, is a non-invasive stool-based test for colorectal cancer screening, approved by the FDA and covered by Medicare for average-risk adults aged 45–85. The company also operates Oncotype DX, a genomic test that guides treatment decisions for breast, prostate, and colon cancer patients. These precision diagnostics address a significant market opportunity in the United States, where colorectal cancer remains the second leading cause of cancer-related deaths among men and women combined.

Main revenue and product drivers for Exact Sciences

Cologuard and Oncotype DX generated the majority of Q1 2026 revenue growth. Cologuard benefits from expanded Medicare coverage and rising awareness of non-invasive screening options, while Oncotype DX continues to gain adoption among oncologists and pathologists as a standard-of-care test for treatment planning. The company is also investing in pipeline expansion to develop additional precision oncology tests, strengthening its competitive position in the $50+ billion global cancer diagnostics market.

The stock traded at $52.45 USD on 05/10/2026 on Nasdaq, according to Yahoo Finance as of 05/10/2026. Cash position strengthened during the quarter to support pipeline expansion and strategic investments in precision oncology capabilities.

Why Exact Sciences matters for US investors

Exact Sciences is a pure-play US healthcare company listed on Nasdaq, making it directly accessible to American retail investors. The company operates primarily in the United States, where it benefits from favorable reimbursement policies, an aging population at higher risk for cancer, and growing demand for non-invasive diagnostic solutions. As precision medicine becomes standard in oncology, Exact Sciences' market position and revenue growth trajectory reflect broader trends in personalized healthcare adoption across US medical systems.

Conclusion

Exact Sciences delivered solid Q1 2026 results with 12% revenue growth and continued momentum in its core Cologuard and Oncotype DX franchises. The company's strengthened cash position and ongoing pipeline investments position it to capture additional market share in precision oncology diagnostics. For US investors seeking exposure to the growing cancer diagnostics market, Exact Sciences represents a established player with demonstrated revenue growth and a clear strategic direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.